

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Colorectal Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Clinical observations of tumor sidedness have revealed which tumors to be more likely to respond to anti-EGFR therapies?**
 - Right-sided tumors
 - Left-sided tumors**
 - Right and left-sided tumors respond equally to anti-EGFR therapies
- Which of the following best describes outcomes with encorafenib, binimetinib and cetuximab as second-line treatment for patients with metastatic colorectal cancer (mCRC)?**
 - Overall survival (OS) with the doublet combination is significantly greater than with the triplet
 - OS with the triplet combination is significantly greater than with the doublet
 - OS with the doublet and triplet regimens are equivalent**
- The ongoing Phase III BREAKWATER study is evaluating chemotherapy in combination with _____ as first-line therapy for patients with BRAF V600E-mutant mCRC.**
 - Encorafenib/binimetinib/cetuximab
 - Encorafenib/binimetinib/panitumumab
 - Encorafenib/cetuximab**
 - Dabrafenib/trametinib/cetuximab
 - Dabrafenib/trametinib/panitumumab
 - Dabrafenib/cetuximab
- Mutational analysis of patients treated with chemotherapy and bevacizumab in the TRIBE study revealed the worst outcomes for patients with mutations in which gene(s)?**
 - RAS
 - BRAF**
 - TP53